CPAP machine maker posts record revenue but shares sink
ResMed, an ASX-listed CPAP maker, reported record Q4 revenue of US$1.5B and FY2025/26 revenue of US$5.7B, up 10%. Full-year net income rose 9% to US$1.5B, but gross margin was 62.3% versus 62.7% expected, which the company attributed to inflation. ResMed plans modest 2026/27 price increases. Shares fell 4.9% to $29.94.
How this was made
The 30-second read
Why it matters
The key tradable takeaway is the combination of record revenue growth with a gross margin miss attributed to inflation, plus guidance that price increases will be only modest in 2026/27.
Market read
Traders can use the margin miss, inflation explanation, and modest pricing plan to reassess near-term earnings estimates and risk for RMD.
What to watch
The article notes Americas margin softness offset by rest-of-world software-as-a-service strength, implying regional mix could improve even if consolidated gross margin stays pressured.
Background
ResMed is a CPAP and sleep-apnea treatment provider, reporting quarterly and full-year financials with management commentary on inflation and product/software initiatives.
Ticker impact
ResMed reported record Q4 revenue but gross margin missed expectations (62.3% vs 62.7%) and blamed inflation, sending shares down 4.9% premarket.
Bearish bias for the next few sessions as traders reprice gross-margin durability and inflation pass-through.
The article provides a concrete margin miss, management’s inflation explanation, and a limited pricing response, which are direct inputs to near-term estimates.
Market effects
Highlights pricing power limits for medical device makers facing inflation, potentially pressuring sentiment across sleep-apnea and durable medical equipment peers.
ASX-listed trading sentiment may spill into AU healthcare/medical device risk appetite given the large YTD drawdown mentioned.
Inflation-driven margin pressure and GLP-1 demand tailwinds are globally relevant for medtech earnings models.
Counterpoint
Revenue growth and a new product cycle (fabric masks) plus software/AI engagement could offset margin pressure longer than the market expects.
Key entities
- companyResMed
ASX-listed CPAP machine maker reporting record revenue but gross margin below expectations, with inflation blamed and modest price increases planned.
- executiveMick Farrell
CEO cited inflation as affecting customers globally and discussed innovation drivers.
- executiveAaron Bloomer
CFO/finance leader who said ResMed will enact very modest price increases over 2026/27.
- productDawn
Generative AI health concierge chatbot that answered 1.5 million inquiries since launch about three months ago.
- analystCraig Wong-Pan
RBC Capital Markets analyst noting revenue in-line but gross margin slight miss and other factors weighing on the stock.
